A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2024.107701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Perpetual Nyame und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: GPI-Linked Proteins, Antigens, CD, HIV-1, Virus Release. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
The introduction of combined antiretroviral therapy (cART) has greatly improved the quality of life of human immunodeficiency virus type 1 (HIV-1)-infected individuals. Nonetheless, the ever-present desire to seek out a full remedy for HIV-1 infections makes the discovery of novel antiviral medication compelling. Owing to this, a new late-stage inhibitor, Lenacapavir/Sunlenca, an HIV multi-phase suppressor, was clinically authorized in 2022. Besides unveiling cutting-edge antivirals inhibiting late-stage proteins or processes, newer therapeutics targeting host restriction factors hold promise for the curative care of HIV-1 infections. Notwithstanding, bone marrow stromal antigen 2 (BST2)/Tetherin/CD317/HM1.24, which entraps progeny virions is an appealing HIV-1 therapeutic candidate. In this study, a novel drug screening system was established, using the Jurkat/Vpr-HiBiT T cells, to identify drugs that could obstruct HIV-1 release; the candidate compounds were selected from the Ono Pharmaceutical compound library. Jurkat T cells expressing Vpr-HiBiT were infected with NL4-3, and the amount of virus release was quantified indirectly by the amount of Vpr-HiBiT incorporated into the progeny virions. Subsequently, the candidate compounds that suppressed viral release were used to synthesize the heterocyclic compound, HT-7, which reduces HIV-1 release with less cellular toxicity. Notably, HT-7 increased cell surface BST2 coupled with HIV-1 release reduction in Jurkat cells but not Jurkat/KO-BST2 cells. Seemingly, HT-7 impeded simian immunodeficiency virus (SIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) release. Concisely, these results suggest that the reduction in viral release, following HT-7 treatment, resulted from the modulation of cell surface expression of BST2 by HT-7.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
- Laboratory of Hemato-Immunology, Graduate School of Health Sciences, University of the Ryukyus, Okinawa, Japan.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; Department of Drug Discovery, Science Farm Ltd, Kumamoto, Japan.
- Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Förderung
- National Institutes of Health
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- National Institute of Allergy and Infectious Diseases
- Kumamoto University
Zitieren
APA
Nyame, P., Togami, A., Yoshida, T., Masunaga, T., Begum, M. M., Terasawa, H., Monde, N., Tahara, Y., Tanaka, R., Tanaka, Y., Appiah-Kubi, J., Amesimeku, W. A. O., Hossain, M. J., Otsuka, M., Yoshimura, K., Ikeda, T., Sawa, T., Satou, Y., Fujita, M., …, & Monde, K. (2024). A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107701
Vancouver
Nyame P, Togami A, Yoshida T, Masunaga T, Begum MM, Terasawa H, et al. A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107701
BibTeX
@article{Nyame2024,
author = {Nyame, Perpetual and Togami, Akihiro and Yoshida, Tomofumi and Masunaga, Takuya and Begum, Mst Monira and Terasawa, Hiromi and Monde, Nami and Tahara, Yurika and Tanaka, Reiko and Tanaka, Yuetsu and Appiah-Kubi, Joyce and Amesimeku, Wright Andrews Ofotsu and Hossain, Md Jakir and Otsuka, Masami and Yoshimura, Kazuhisa and Ikeda, Terumasa and Sawa, Tomohiro and Satou, Yorifumi and Fujita, Mikako and Maeda, Yosuke and Tateishi, Hiroshi and Monde, Kazuaki},
title = {A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2024.107701}
}
EUVIMED